New Delhi: India is set to see the launch of Afrezza—the only rapid-acting, inhaled insulin to help control high blood sugar in adults with type 1 or type 2 diabetes—ten years after the treatment was ...

announced today that the Central Drugs Standard Control Organisation (CDSCO) in India has approved Afrezza (insulin human) Inhalation Powder in adults. The CDSCO decision follows existing ...

Drugmaker Cipla has got regulatory approval to market Afrezza, a rapid acting insulin delivered through an inhaler, as compared to other insulins given through injections. The Central Drugs ...

Cipla secures CDSCO approval for Afrezza, a rapid-acting insulin delivered through an inhaler, offering a convenient solution for diabetes management in India. The drug is the first and only ...

An “inhaled insulin” is set to join the repertoire of options available to people with diabetes, as drugmaker Cipla completes last mile procedures to import Afrezza from US’ MannKind ...

Afrezza is a rapid-acting insulin delivered through an inhaler compared to current insulins which are given as injections. Taken at the beginning of a meal, the medication dissolves rapidly upon oral ...

announced today that the Central Drugs Standard Control Organisation (CDSCO) in India has approved Afrezza (insulin human) Inhalation Powder in adults. The CDSCO decision follows existing approvals in ...